Association between Cyclin D1 Polymorphisms and Risks of Urothelial Carcinoma

• Main Authors: Kuang-Hung Hsiao, 蕭光宏
• Other Authors: Wen-Jeng Wu
• Format: Others
• Language: zh-TW
• Published: 2008
• Online Access: http://ndltd.ncl.edu.tw/handle/38766973297744095789

碩士 === 高雄醫學大學 === 醫學研究所 === 96 === Abstract Objective Urothelial carcinoma (UC) is the common cancer of the urinary tract tumors, it includes pelvic cancer、 bladder cancer and ureter cancer. The prevalence of urothelial carcinoma is geographic different. According to reports from other countries, urinary bladder cancer is the most common , pelvic cancer and ureter cancer are relatively rare. What caused urothelial carcinoma so far is not well understood, especially the high prevalence of upper urothelial carcinoma in Taiwan. Therefore, the aims of this experiment is to evaluate the relationship between the CCND1 870、CCND1 1722 polymorphisms and urothelial carcinoma. Materials and methods The research design is the case-control study, which is depend on hospital document as the foundation. 249 healthy controls and 143 patients with urothelial carcinoma (pelvic cancer 、ureter caner and bladder cancer) were enrolled in this study. All subjects had complete collections of clinical histories and laboratory data. The two most common cyclin D1 polymorphisms (CCND1 G870A、 CCND1 G1722C) were determined using the polymerase chain-reaction fragment length polymorphism (PCR-RFLP) method. All statistical analyses were performed with SPSS software version 15.0 (SPSS Inc., Chicago, IL, USA). A two sided P value <0.05 was considered statistically significant. All the polymorphisms studied conformed to Hardy–Weinberg equilibrium. Result Total 392 cases were enrolled in the study. In the classification of urothelial carcinoma, 73 people (51%) have bladder cancer, 25 people (17.5%) have ureter cancer, 27 people (18.9%) have pelvic cancer, and 18 people (12.6%) have two kinds of urothelial carcinoma. Separately compare CCND1 G870A and CCND1 G1722C polymorphisms with urothelial carcinoma, the analysis results revealed the genotypes of CCND1 870 have no difference in urothelial carcinoma, but CCND1 870 GA and AA genotypes will significantly reduce the risk to suffer serious (invasive or advanced) upper urinary tract urothelial carcinoma; but on the other hand, CCND1 870 GA and AA genotypes will also increase the risk to suffer bladder cancer. Otherwise, CCND1 1722 GC genotype will increase the risk to suffer urothelial carcinoma 1.7 fold, and GC type genotype will also increase the risk in upper urinary tract urothelial carcinoma up to 2.1 fold. Discussion In this study, we found the prevalence of upper tract urothelial cell carcinoma (pelvic cancer and ureter cancer) were more common than other western countries respectively. Our result showed CCND1 870 A allele plays a different role in upper urinary tract urothelial carcinoma and bladder cancer, the CCND1 870 GA and AA genotypes will reduce the risk to suffer serious (invasive or advanced) upper urinary tract urothelial carcinoma, but these genotypes will increase the risk to suffer bladder cancer. Otherwise, CCND1 1722 GC genotype will increase higher risk in upper tract urothelial carcinoma (2.1 fold) than urothelial carcinoma (1.9 fold). It means C allele in CCND1 1722 plays an important role in upper urinary tract urothelial carcinoma. This is the first article to discuss the relationship between CCND1 G1722C polymorphism and urothelial carcinoma, we hope to discuss why upper urinary tract urothelial carcinoma patients are so common in our country and to find more effect therapy to different patients in the future.